Telix Pharmaceuticals Shareholders Urged to Act in Class Action Lawsuit by The Gross Law Firm
On December 11, 2025, The Gross Law Firm released an important notice directed at shareholders of Telix Pharmaceuticals Ltd. (NASDAQ: TLX). This notification underscores the importance of acting swiftly, as a class action lawsuit has been lodged against the company. Those who acquired shares of TLX from February 21, 2025, to August 28, 2025, are particularly encouraged to get in touch with the firm regarding the potential of being appointed as lead plaintiffs in this case.
The allegations in the lawsuit suggest significant discrepancies between what was stated by Telix and the reality of their business practices. Specifically, it is claimed that during the class period, the company's representatives issued misleading statements that overstated not only their progress regarding therapeutic candidates for prostate cancer but also the reliability of their supply chain and partnerships. These inadequacies in disclosure have led to a situation where the company's public statements about its operations and future prospects were ultimately false and misleading, lacking a reasonable basis.
The upcoming deadline for shareholders to file as lead plaintiffs is January 9, 2026, highlighting the urgency of the situation. All shareholders who purchased TLX shares in the specified period are advised to register their information without delay through a provided link, which guarantees enrollment into a portfolio monitoring system that will update them on the case's status throughout its progression. Participation is straightforward as registering does not incur any costs or obligations for the shareholders.
The Gross Law Firm has established a reputation as a leading class-action law firm nationally, focusing on safeguarding the rights of investors adversely affected by fraudulent activities and unethical business behavior. Their commitment drives them to hold companies accountable to ethical practices, ensuring that investors do not suffer losses due to deceit or misrepresentation.
Anyone seeking further information or wishing to participate in the lawsuit can contact The Gross Law Firm directly. Their office is located at 15 West 38th Street, 12th Floor, New York, NY, 10018. They can also be reached via email or phone.
As legal proceedings unfold, it is crucial for affected shareholders to remain informed and proactive. Shareholders should thoroughly investigate their positions and take appropriate measures to ensure their rights and investments are protected in this legal combat. As the situation develops, continual updates will be made available for those registered, keeping them well-informed of essential developments in the case.
The allegations in the lawsuit suggest significant discrepancies between what was stated by Telix and the reality of their business practices. Specifically, it is claimed that during the class period, the company's representatives issued misleading statements that overstated not only their progress regarding therapeutic candidates for prostate cancer but also the reliability of their supply chain and partnerships. These inadequacies in disclosure have led to a situation where the company's public statements about its operations and future prospects were ultimately false and misleading, lacking a reasonable basis.
The upcoming deadline for shareholders to file as lead plaintiffs is January 9, 2026, highlighting the urgency of the situation. All shareholders who purchased TLX shares in the specified period are advised to register their information without delay through a provided link, which guarantees enrollment into a portfolio monitoring system that will update them on the case's status throughout its progression. Participation is straightforward as registering does not incur any costs or obligations for the shareholders.
The Gross Law Firm has established a reputation as a leading class-action law firm nationally, focusing on safeguarding the rights of investors adversely affected by fraudulent activities and unethical business behavior. Their commitment drives them to hold companies accountable to ethical practices, ensuring that investors do not suffer losses due to deceit or misrepresentation.
Anyone seeking further information or wishing to participate in the lawsuit can contact The Gross Law Firm directly. Their office is located at 15 West 38th Street, 12th Floor, New York, NY, 10018. They can also be reached via email or phone.
As legal proceedings unfold, it is crucial for affected shareholders to remain informed and proactive. Shareholders should thoroughly investigate their positions and take appropriate measures to ensure their rights and investments are protected in this legal combat. As the situation develops, continual updates will be made available for those registered, keeping them well-informed of essential developments in the case.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.